Companies / Switzerland
Novartis Challenges India's Patent Laws
January 2007 | Legal NewsIn a highly controversial move, Swiss multinational Novartis is seeking to overturn India's intellectual property laws after the local patent office decided to decline the patent for Gleevec (imatinib), Novartis' groundbreaking cancer treatment. It is BMI's view that whatever outcome of this development, it will have a major impact on the global pharmaceutical industry. If India's authorities continue to ignore the patent, Novartis and many of its peers may exit the country and invest elsewhere, seriously damaging India's economic future. Conversely, if Novartis succeeds, the production of cheap generics in India could be permanently compromised, which could result in dire
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
